Hefei Lifeon Pharmaceutical (SZ:003020) Xin Lang Cai Jing·2026-01-09 09:05Group 1 - The core point of the article is that Lifan Pharmaceutical's subsidiary, Chengzhi Biological, has received approval from the National Medical Products Administration for the drug registration certificate of Loxoprofen Sodium Oral Solution, marking a significant milestone for the company [1] - Loxoprofen Sodium is a non-steroidal anti-inflammatory drug (NSAID) with effective analgesic, anti-inflammatory, and antipyretic properties [1] - As of the announcement date, there are no imported products approved for sale in the domestic market, making Chengzhi Biological the eighth company in China to hold the drug registration for this product [1] Group 2 - The acquisition of the drug registration certificate will further enrich Lifan Pharmaceutical's product pipeline and enhance its market competitiveness [1] - However, the production and sales of the drug remain subject to policy and market factors, indicating potential uncertainties [1]